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Abstract
Objectives The aim of this study is to improve the accuracy of
dynamic contrast-enhanced ultrasound (DCE-US) for prostate
cancer (PCa) localization bymeans of amultiparametric approach.
Materials and Methods Thirteen different parameters related to
either perfusion or dispersion were extracted pixel-by-pixel from
45 DCE-US recordings in 19 patients referred for radical prosta-
tectomy. Multiparametric maps were retrospectively produced
using a Gaussian mixture model algorithm. These were subse-
quently evaluated on their pixel-wise performance in classifying
43 benign and 42 malignant histopathologically confirmed re-
gions of interest, using a prostate-based leave-one-out procedure.
Results The combination of the spatiotemporal correlation (r),
mean transit time (μ), curve skewness (κ), and peak time (PT)
yielded an accuracy of 81%± 11%, which was higher than the
best performing single parameters: r (73%), μ (72%), and wash-
in time (72%). The negative predictive value increased to
83%± 16% from 70%, 69% and 67%, respectively. Pixel inclu-
sion based on the confidence level boosted these measures to
90% with half of the pixels excluded, but without disregarding
any prostate or region.
Conclusions Our results suggestmultiparametric DCE-US anal-
ysis might be a useful diagnostic tool for PCa, possibly
supporting future targeting of biopsies or therapy. Application
in other types of cancer can also be foreseen.
Key points
• DCE-US can be used to extract both perfusion and
dispersion-related parameters.
• Multiparametric DCE-US performs better in detecting PCa
than single-parametric DCE-US.
• Multiparametric DCE-US might become a useful tool for
PCa localization.




CUDI Contrast-ultrasound dispersion imaging
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ROC Receiver operating characteristic
ROI Region of interest
TIC Time-intensity curve
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Prostate cancer (PCa) is the most prevalent form of cancer
among American men, representing 26% of the new cases
and approximately 10% of the cancer-related deaths [1].
Therefore, a reliable and minimally invasive diagnostic tool
for PCa is of paramount importance. During the last decade of
the 20th century, the introduction of prostate-specific antigen
(PSA) blood testing led to a dramatic increase of the number
of PCa diagnoses as well as a growing number of patients
exhibiting low-risk or indolent disease [2]. Overdiagnosis
and overtreatment are considered substantial problems due
to the limited positive predictive value (PPV) of screening
tools such as PSA level assessment and digital rectal exami-
nation [3, 4]. Therefore, the definitive diagnosis of PCa still
relies on ≥10 core systematic biopsy [5]. There is a high inci-
dence of biopsy-related complications [6, 7] and a consider-
able fraction of malignancies is identified only in repeat biop-
sy [8]. This stresses the demand for an imaging modality that
is able to localize or rule out prostatic malignancies. Such a
technique could eventually serve as a localization tool for
targeted biopsy [9, 10], or assist in patient selection and treat-
ment planning for organ-sparing focal therapy [11].
Currently, multiparametric magnetic resonance imaging
(mpMRI) seems the most promising imaging method for
PCa localization [12]. A recent meta-analysis reported an ap-
preciable average sensitivity of 74% and specificity of 88%,
with negative predictive values (NPVs) that ranged from 65%
to 94% [13]. In view of the advantages of transrectal ultra-
sound (TRUS) over MRI in terms of costs, time, resolution,
and practicality at bedside, this paper proposes a
multiparametric approach of TRUS.
Unfortunately, B-mode TRUS is not considered sufficient-
ly accurate for stand-alone tumour detection [14, 15]. Since
clinically relevant prostatic malignancies are characterized by
angiogenesis and neovascularization [16, 17], increased per-
fusion has been proposed as a marker for PCa. Moreover, it
was observed that the microvascular density correlates with
cancer aggressiveness [18]. However, Doppler imaging was
not found sufficiently accurate to capture these vascular
changes due to its limited sensitivity for small flows [19,
20]. The use of intravenously injected ultrasound contrast
agents (UCAs) in the TRUS procedure, that is, dynamic
contrast-enhanced ultrasound (DCE-US) imaging, also allows
the visualization of the vascular fraction and perfusion.
Contrast-specific imaging modes are even able to image mi-
crocirculation at a capillary scale [21]. Again, despite the re-
ported improvements in tumour detection rate [22, 23],
targeted biopsies based on visual interpretation of contrast-
enhanced US alone are not considered viable to replace sys-
tematic biopsy [9, 24]. This might be explained by the incon-
sistent, ambiguous effect of angiogenesis on blood flow [25].
Whereas diminished vasomotor control and formation of
shunts cause an elevation in perfusion, the high tortuosity
and permeability, with rising interstitial pressure, lead to the
opposite effect [16, 17].
Tissue characterization by DCE-US thus requires a more
detailed assessment of the UCA kinetics in the prostate. UCAs
are composed of encapsulated micron-sized gas bubbles that
remain a few minutes in the vasculature [26–28], and their
behaviour can be assessed by looking at the time-intensity
curve (TIC), which is the evolution of echo intensity over time
in a certain area. For example, malignant areas in DCE-US
recordings are found to be marked by rapid and enhanced
inflow compared to similar benign regions in the prostate
[29, 30]. Several parameters have been extracted from the
TICs in order to mark relevant alterations in perfusion; these
are, e.g., the wash-in rate [31, 32], time to peak (PT) [33, 34],
time to appearance (AT) [33, 34], peak intensity (PI) [32–35],
and the area under the curve [33, 36]. In addition to these
perfusion-related parameters, angiogenic microvasculature
changes can also be detected by assessing UCA dispersion
[37]. Contrast US dispersion imaging (CUDI) was recently
developed to analyse the dispersion kinetics of a microbubble
contrast bolus in a DCE-US recording. The dispersive behav-
iour has been assessed with curve fitting [37], or similarity
analysis [38, 39]. In these methods, the TIC of each pixel in
the imaging plane is either fitted by a convective diffusion
model or compared to its neighbouring TICs, respectively.
Though different in nature, the parameters acquiredwith these
methodswere shown to have appreciable levels of sensitivity and
specificity for PCa detection. Hence, we hypothesize that a com-
bination of complementary parameters related to perfusion and
dispersion allows us to localize prostatic carcinoma with an even
higher level of accuracy. PCa is a multifocal and heterogeneous
disease whose appearance depends on cancer type, grade and
topography [24]. A multiparametric approach reduces the risk
of missing tumours that are invisible to one of the parameters
and may be able to discriminate prostatic diseases that mimic
malignant characteristics, like prostatitis [40].
Since the performance of a multiparametric approach
is not dependent on a single threshold, it cannot be eval-
uated using conventional receiver operating characteristic
(ROC) analysis [41, 42]. Instead, a multiparametric ap-
proach requires a classification algorithm to combine the
parameters into a single parametric map. Many algo-
rithms have been used in biomedicine for classification;
in particular, Gaussian mixture models (GMMs), support
vector machines and artificial neural networks have been
extensively employed [43–45]. GMMs have been chosen
for our multiparametric evaluation as these are fast,
purely based on data (no need for additional physical
modelling) and facilitate the definition of classification
confidence. Moreover, GMMs were reported to perform
better than neural networks in mammographic tumour
identification [45].
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In this paper, we take into account thirteen perfusion- and
dispersion-related parameters as well as the echo intensity on
the TRUS image. Retrospectively, the most useful parameters
are selected and combined using histopathologically deter-
mined regions of interest (ROIs) in order to improve the ac-
curacy of DCE-US for the localization of PCa.
Materials and methods
Data acquisition
Nineteen PCa patients that were scheduled for radical prosta-
tectomy underwent a transrectal DCE-US scan prior to sur-
gery. The procedures were approved by the local ethics com-
mittee and carried out at the Academic Medical Center
(Amsterdam, The Netherlands). All patients signed an in-
formed consent. Patients below the age of 18 or with contra-
indications for the administration of contrast agents as defined
by the European Medicines Agency were excluded. Patients
with a tumour of Gleason score ≥ 3 + 3 and a size suitable for
our analysis (see section BHistopathological Analysis^) were
selected for this study. The patient and tumour characteristics
are summarized in Table 1.
For the procedure, 2.4 mL of a SonoVue® UCA
microbubble suspension (Bracco, Milan, Italy) was intrave-
nously administered. This suspension consists of encapsulated
sulphur hexafluoride bubbles with an average diameter of
2.5 μm [46]. Two-minute recordings were subsequently per-
formed with an iU22 US scanner (Philips Healthcare, Bothell,
WA, USA), generally using a 3-MHz to 10-MHz-ranged
endocavity US probe (C10-3v). For one patient, an endocavity
probe with a range from 4 MHz to 8 MHz (C8-4v) was used
due to availability issues. The measurements were carried out
in contrast-specific mode based on a power modulation pulse
scheme at a frequency of 3.5 MHz and with a mechanical
index of 0.06 to minimize bubble disruption.
Histopathological analysis
After prostatectomy, the prostates were fixed with a formalin
solution, deprived of the seminal vesicles, sectioned in slices
of ~4 mm and examined by the pathologist as described by
Montironi et al. [47]. The tumours were subsequently delin-
eated by the pathologist. Prior to the parametric analysis,
~0.5 cm2-sized ROIs were manually drawn on the B-mode
US scans to identify areas containing histologically confirmed
malignancy. Histological images were matched to the US
scans based on the position of the imaging plane in a trans-
versal sweep video performed before the contrast recordings.
ROIs were only drawn in areas where the histopathologic
information persisted in the two adjacent slices. The prostatic
boundarywas used to aid the localization. In the sameway, we
positioned similarly sized ROIs in areas that were not depicted
as malignant. This resulted in a dataset containing about
174,000 pixels extracted from 85 ROIs in 45 DCE-US record-
ings in 19 patients, marked as either benign (43 ROIs) or
malignant (42 ROIs). In the end, we were able to include
one to four DCE-US imaging planes per patient.
Data processing and parameter extraction
To assess the dispersive UCA behaviour, the DCE-US record-
ings were analysed by TIC fitting as well as by similarity
analysis. The parametric maps were produced using a
custom-made CUDI program running in Matlab® (2015b,
Mathworks, Natick, MA, USA) [48]. Following the method
described in [37], the data were pre-processed and the extract-
ed TICs were fitted by a modified local density random walk
(LDRW)model. This allowed us to estimate the area under the
curve (α), the mean transit time (μ), the skewness parameter
(κ), and the ratio between the diffusive and convective time
(λ = μκ). In addition, we looked at the variance (var) which is
the second moment of the curve [49], and the fitting interval
(int) between the PT and the truncation time where UCA re-
circulation occurs [37].
For the similarity analysis, the data were pre-processed as
described in [39]. The spectral coherence (ρ) [38] and the
spatiotemporal correlation coefficient (r) [39] were then cal-
culated. For these parameters, the TIC of a single pixel is
compared to those in a ring-shaped kernel of 1.0 to 2.5 mm
in radius, as this size allows us to visualize similarity on the
scale of early angiogenesis [38].
Based on the processing in [37], we also extracted the PI,
the AT (where the TIC reaches 5% of the PI) and the PT (the
time where the intensity is the highest). In addition, the wash-
Table 1 List of patient and tumour characteristics
Characteristic Mean Median Range
Age (yrs) 62.7 64 52 – 73
PSA level (ng/mL) 8.7 7.3 2.9 – 31.9







3 + 3 6
3 + 4 7
4 + 3 4
3 + 5 1
4 + 5 1
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in time (WIT, the time period between AT and the point where
the TIC reaches 95% of the PI), and the full width half maximum
(FWHM) were considered as parameters of interest. A full list of
the investigated parameters is reported in Table 2.
Classification procedure
Gaussianmixture modelling is a widely known approach in clus-
ter analysis [50, 51] and data classification [52, 53]. GMMs
describe a set of observations (i.e. pixels) in (multi)parametric
space by a mixture of normal distributions. Using two pre-
determined training subsets of benign and malignant observa-
tions, the class-specific probability distributions can be comput-
ed. Subsequently, each pixel in the test set is classified according
to these distributions. We define a measure for the confidence of
classification by comparing the probabilities, p, of the observa-
tion being benign or malignant. This confidence level, P, conve-
niently ranging from 0 to 1, is described by P ¼ 2pApAþpB −1, where
A denotes the class with highest probability.
The GMM classification algorithm was implemented in
Matlab® using the statistical analysis toolbox. The parameters
were normalized to the 90th percentile to ensure equal
weighting, and training was performed using an iterative
expectation-maximization algorithm [54]. Since the GMM al-
gorithm is very fast, it was feasible to evaluate all possible
combinations of one to four distinct parameters. We did not
take into account more than four parameters to avoid
overfitting.
To evaluate the performance of the classifier, the procedure
was tested on each of the prostates whilst using the observa-
tions in other prostates as the training set. The outcomes of this
leave-one-out analysis were averaged over all prostates. We
quantified the classification performance by computing the
accuracy, sensitivity, specificity, PPV and NPV [41, 42].
Whereas sensitivity and specificity indicate the percentage of
correctly classified malignant and benign pixels, respectively,
PPV and NPV reflect the percentage of pixels classified re-
spectively as malignant and benign that were correct. In addi-
tion, accuracy represents the overall correct classification per-
centage. Since the NPVis of paramount importance in order to
avoid missing clinically relevant PCa lesions, we optimized
the classifier based on this measure as well as on the accuracy.
Pixel exclusion
The TIC measurement quality usually differs from pixel to
pixel. To ensure the quality of the classification, it is important
to identify pixels that are likely to be misclassified. As stated,
the classification algorithm indicates the confidence of the
classification by the level P. Also, we consider the coefficient
of determination, R2, describing how well the TIC can be
fitted by the modified LDRW model, and the absolute proba-
bility of an observation belonging to its class. Large healthy
vessels are more likely to show early arrival of the bolus,
which complicates the use of perfusion parameters to mark
malignancy. Therefore, we also evaluated the classifier’s per-
formance after excluding the pixels with the lowest PT for
each plane.
Results
Based on accuracy, the combination of r,μ,κ, and PTyielded the
best accuracy (mean ± standard deviation = 81 ± 11%). The
highest NPV was found for the parameters var, μ, r, and int
(87 ± 15%), but with two of the other performance measures
being inferior compared to first set. The highNPVand sensitivity
can be explained by a low number of false negatives. We found
the parameter distributions best described by a single Gaussian
function per variable. The outcomes were compared to the per-
formance of individual parameters. The best-performing param-
eters of all three analyses—μ for curve fitting, r for similarity
analysis and WIT for conventional perfusion analysis—were
evaluated by a ROC-based threshold optimization as well as
GMM classification in one-dimensional parametric space. As
shown in Table 3, the multiparametric classification has a higher
performance than the ROC-analysed single parameters, irrespec-
tive of the measure used. Since not all individual parameters are
well described by a single Gaussian distribution, a non-tailored
GMM approach for the single parameters yielded less stable
results in terms of the balance between sensitivity and specificity.
Table 2 Full list of the parameters considered for multiparametric
analysis, with symbols and units
Symbol Parameter name Unit
B-mode ultrasound
Greylevel Echo intensity a.u.
Contrast-enhanced ultrasound
WIT Wash-in time s
AT Appearance time s
PT Peak time s
PI Peak intensity a.u.
FWHM Full width half maximum s
Fitting analysis
κ Skewness parameter s-1
μ Mean transit time s
λ Convective-diffusion ratio -
α Area under the curve a.u.
var Variance a.u.
int Interval time s
Similarity analysis
ρ Spectral coherence -
r Correlation coefficient -
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Even though accuracy and NPVare considered the most impor-
tant performancemeasures, a reliable technique requires the other
measures to be sufficiently high as well.
In the BMaterials and methods^ section, we mentioned
feature-based exclusion of pixels to decrease the number of
misclassifications in the multiparametric map. Figure 1 shows
the changes in accuracy after pixel exclusion based on classi-
fication confidence P, absolute probability, R2, and PT. It re-
veals that P correctly reflects the confidence and that it is the
most suitable measure to identify pixels with a high risk of
misclassification. The results of the multiparametric classifi-
cation after pixel exclusion based on this measure are depicted
in Figures 2a and b for a parameter set containing r, μ, κ, and
PT and a set containing var, μ, r, and int, respectively. The
exclusion of pixels is equally distributed over benign and
malignant pixels, as well as over patients and regions; exclu-
sion would, therefore, not result in extra PCa foci being
missed.
To illustrate the results of whole-prostate classification and
the effect of pixel exclusion, the US and classification maps as
well as histological images of two patients are shown in
Figure 3. For the first set in Figure 2, the accuracy and NPV
have grown from 81 ± 11% to 90 ± 10% and from 83 ± 16% to
91 ± 13% with 51 ± 17% of the pixels remaining. These
values are 72 ± 10% to 90 ± 7% and 87 ± 15% to 89 ± 15%
for the second set, again with 51 ± 14% of the pixels included.
These exclusion percentages include the 4.5 ± 3.2% of pixels
that could not be fitted by the LDRW model. For reference,
Figure 4 depicts the individual, normalized parametric maps
that contribute to a multiparametric image.
Discussion
According to today’s guidelines [5], reliable PCa diagnosis
requires a ≥10 core systematic biopsy under US guidance
and local anaesthesia. In recent years, an increasing emphasis
has been laid on imaging and targeted biopsy [9] in view of the
number of reported complications [6], over-diagnoses due to
the overestimation of pathologically insignificant lesions [3],
and under-diagnoses due to small high-risk PCa foci being
missed [8]. Contrast-enhanced US allows the extraction of
multiple parameters that have potential to serve as a diagnostic
marker for malignancy. The presented multiparametric ap-
proach combines perfusion-related parameters from conven-
tional DCE-US and dispersion-related parameters from CUDI
by means of a GMM classifier.
The optimal subset of parameters comprises r, μ, κ, and PT
and thus features parameters from all analysis methods. Of
these parameters, r contributes most to the outcome, which is
consistent with previous publications on CUDI [39]. As μ and
κ jointly describe the shape of LDRW-modelled TIC [55], it is
not surprising the combination of these two has the greatest
added value to r. Finally, the addition of PT offers a slight
improvement to the accuracy (80% to 81%). Though early
enhancement is a strong marker of malignancy, the quantitative
use of the PT is normally complicated by its strong dependence
on operator and circulation time [34]. In combination with the
other parameters, however, the PT is able to further delineate
malignant and benign regions. Despite its good performance as
a single parameter, the WIT is not included in the
multiparametric sets.We expect that this is the result of the high
correlation betweenWITand μ (Pearson’s r: 0.88), making this
parameter redundant after inclusion of μ.
We have shown that observations that are likely to be
misclassified can be recognized by their low confidence level.
Excluding low-confidence pixels from the multiparametric
map increases the reliability of the classification. A confidence
Table 3 Performance of the classification methods using specified
parameters
ROC Analysis Single GMM Multiparametric
GMM




Accuracy (%) 72 72 73 73 71 67 81 72
Sensitivity (%) 75 74 71 88 90 65 79 90
Specificity (%) 68 70 75 51 47 71 80 50
PPV (%) 76 75 76 70 63 70 85 65
NPV (%) 67 69 70 84 85 72 83 87
The used abbreviations are listed in the Abbreviations List and Table 2
The best performing perfusion-related parameter as well as best parame-
ters of curve fitting and similarity analysis were evaluated using ROC
analysis and single-parameter GMM. Multiparametric results are shown
of the parameter sets with the highest accuracy (r, μ, κ, PT) and NPV (var,
μ, r, int)
Fig. 1 Accuracy of the Gaussian mixture model classifier by exclusion
of pixels based upon their confidence level, coefficient of determination,
absolute probability, and peak time. The classifier was run using a set of
parameters containing r, μ, κ, and PT
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threshold of 0.5 leads to an average pixel exclusion of 36
± 15% per prostate (ranging from 8 to 67%). In general, the
pixel exclusion approach resulted in disregarding pixels in the
areas where benign regions border on malignant ones rather
than pixels in specific prostates. As can be seen in Figure 2,
exclusion does not favour malignant or benign pixels specif-
ically. Figure 3 shows typical examples of classification maps.
There is a high correspondence between the maps and histology,
Fig. 3 The B-mode transrectal
ultrasound, confidence-weighted
classification image, exclusion-
classification images with a
threshold of P > 0.5 and
histopathological images of
patient A (a t/m d) and patient B,
(e t/m h). In the classification
images, red regions are classified
as malignant (i.e. suspicious) and
green regions as benign (i.e. not
suspicious). In the
histopathological images,
malignant areas are indicated with
red. Parameters: r, μ, κ, and PT.
ROIs are shown in overlay to the
B-mode images
Fig. 2 Performance of the Gaussian mixture model classifier upon
exclusion of pixels with the lowest confidence using an increasing
confidence threshold for (a) r, μ, κ, PT and (b) var, μ, int, r. The bars
represent the percentage of benign (grey) and malignant (dark) pixels that
are still included; the lines represent the evolution of accuracy (blue
squares ■), NPV (red triangles▲), and PPV (green circles ●)
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even though small regions remain misclassified after pixel exclu-
sion. Due to the preservation of the correctly classified malignant
regions, these results are clinically relevant for, e.g. targeted bi-
opsy. Because the current analysis faces limitations with respect
to the registration of US imaging planes with histology slices, we
made use of histologically proven ROIs. These ROIs were ~0.5-
cm2 sized, which resembles the critical size of clinically relevant
foci [47]. In the future, three-dimensional US models would
enable us to apply more accurate registration.
In the current analysis, 9 (20%) of the 44 regions predomi-
nantly (>50% of the pixels) classified as negative were
misclassified. In Table 1, Gleason score 3 + 3 represents most
of these false negative regions. The Gleason score, which com-
prises the grade of the two most prevalent histological patterns
found in a stained prostate tissue slice, is an indicator of the stage
and aggressiveness of prostatic carcinoma [56, 57]. Following
recent consensus in prostate grading, Gleason rate score 3 + 3 is
rated as grade group 1, indicating very low-risk disease with high
survival rates and virtually no chance of metastasis [58, 59]. We
believe that the use of a diverse training set (i.e. a set that consists
of malignancies with varying aggressiveness) leads to a higher
risk ofmisclassification in prostates containing very low-grade or
very high-grade PCa, as these are the most different from the
training set average.
The current performance is limited by the small training set in
this study, hampering the possibility to define subgroups accord-
ing to Gleason score. Since the microvascular density is a viable
marker in the staging of PCa [18], this might allow us to distin-
guish low-risk and high-risk PCa. Studies in contrast-enhanced
MRI suggest that perfusion-based discrimination between PCa
grades, and even prostatitis, is possible [60]. In this study, we did
not assess the differences in tumour classification of grades; an
extended dataset would allow such validation in the future.
Another limitation of the study concerns the analysis of small
foci, which, considering the error margin in appointing the ROIs,
could not be included in the study.
DCE-US is not only a valuable modality for diagnosis of
PCa; its use is increasingly mentioned as a tool to monitor the
therapeutic effect of focal therapy. For instance, DCE-US was
found to map tissue devascularisation as well as DCE-MRI
Fig. 4 Example of the four
normalized parametric maps that
serve as input for the best
performing multiparametric map
as shown below. All maps overlay
the B-mode TRUS image. Red
regions are classified as malignant
(i.e. suspicious) and green regions
as benign (i.e. not suspicious) of
which the transparency is scaled
with the confidence level. The
histology slice with tumour tissue
marked red is shown in the upper
right corner of the
multiparametric image
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after interstitial laser therapy [61, 62]. DCE-US has, therefore,
been used for interstitial laser therapy [63] and high-intensity
focused US treatment to visualize viable and devascularized
regions [64, 65]. Apart from the classifier’s aid for tumour
localization and monitoring, the ability of such classifier to
discriminate low-risk and high-risk disease would especially
improve the application of focal therapy and active surveil-
lance strategies.
In conclusion, we see that combined evaluation of contrast-
enhanced ultrasonographic parameters has superior accuracy and
NPV in tumour localization compared to the individual paramet-
ric maps. The GMM-based multiparametric analysis is fast, ver-
satile and allows a reliable confidence estimation of its classifi-
cation. It was shown that pixel exclusion could boost the perfor-
mance even more without disregarding relevant areas of the
prostate. Like in computer-aided diagnosis of breast lesions
[66, 67], an extensive review of other algorithms is recommend-
ed to obtain an overview of the performance, advantages and
drawbacks of other classification methods for the detection of
PCa. In the future, parametric maps derived from other US mo-
dalities such as Doppler and elastography could also be included
[68], as well as the results from other diagnostic tools (e.g. PSA
assessment), but this is beyond the scope of the current study.
Furthermore, this analysis is based on a small patient group, and
we recognize that a more extended validation is needed to derive
global measures for classification. We expect that this method
can also be employed to image other types of cancer.
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